Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies
Neuro-Oncology Advances · 01.01.2024 · 6 (1)
DOI: 10.1093/noajnl/vdae055 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neuro-Oncology Advances, online erschienen am 05.04.2024. Verfasst von Prajwal Ghimire und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Kings College Hospital NHS Foundation Trust, London, UK. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Background
Immunotherapy is an effective “precision medicine” treatment for several cancers. Imaging signatures of the underlying genome (radiogenomics) in glioblastoma patients may serve as preoperative biomarkers of the tumor-host immune apparatus. Validated biomarkers would have the potential to stratify patients during immunotherapy clinical trials, and if trials are beneficial, facilitate personalized neo-adjuvant treatment. The increased use of whole genome sequencing data, and the advances in bioinformatics and machine learning make such developments plausible. We performed a systematic review to determine the extent of development and validation of immune-related radiogenomic biomarkers for glioblastoma.
Methods
A systematic review was performed following PRISMA guidelines using the PubMed, Medline, and Embase databases. Qualitative analysis was performed by incorporating the QUADAS 2 tool and CLAIM checklist. PROSPERO registered: CRD42022340968. Extracted data were insufficiently homogenous to perform a meta-analysis.
Results
Nine studies, all retrospective, were included. Biomarkers extracted from magnetic resonance imaging volumes of interest included apparent diffusion coefficient values, relative cerebral blood volume values, and image-derived features. These biomarkers correlated with genomic markers from tumor cells or immune cells or with patient survival. The majority of studies had a high risk of bias and applicability concerns regarding the index test performed.
Conclusions
Radiogenomic immune biomarkers have the potential to provide early treatment options to patients with glioblastoma. Targeted immunotherapy, stratified by these biomarkers, has the potential to allow individualized neo-adjuvant precision treatment options in clinical trials. However, there are no prospective studies validating these biomarkers, and interpretation is limited due to study bias with little evidence of generalizability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Kings College Hospital NHS Foundation Trust, London, UK.
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
- Department of Oncology, University College London, London, UK.
- Genomics England, London, UK.
- Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
ORCID-Profile: Prajwal Ghimire, Ben Kinnersley, Golestan Karami, Richard Houlston, Keyoumars Ashkan, Marc Modat
Förderung
- Wellcome Trust
Zitieren
APA
Ghimire, P., Kinnersley, B., Karami, G., Arumugam, P., Houlston, R., Ashkan, K., Modat, M., & Booth, T. C. (2024). Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae055
Vancouver
Ghimire P, Kinnersley B, Karami G, Arumugam P, Houlston R, Ashkan K, et al. Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies. Neuro-Oncology Advances. 2024;6(1). doi:10.1093/noajnl/vdae055
BibTeX
@article{Ghimire2024,
author = {Ghimire, Prajwal and Kinnersley, Ben and Karami, Golestan and Arumugam, Prabhu and Houlston, Richard and Ashkan, Keyoumars and Modat, Marc and Booth, Thomas C},
title = {Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies},
journal = {Neuro-Oncology Advances},
year = {2024},
volume = {6},
number = {1},
doi = {10.1093/noajnl/vdae055}
}
EUVIMED